OCULAR THERAPEUTIX, INC Total Contract Liability
OCULAR THERAPEUTIX, INC (OCUL) had Total Contract Liability of $14.00 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2026-08-03
- 2026-06-30: Contract with Customer, Liability $14.00M.
- 2026-03-31: Contract with Customer, Liability $14.00M.
- 2025-12-31: Contract with Customer, Liability $14.00M.
- 2025-09-30: Contract with Customer, Liability $14.00M.
| Period end | Contract with Customer, Liability |
|---|---|
| 2026-06-30 | $14.00M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $14.00M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $14.00M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $14.00M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $14.00M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $14.06M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $14.13M 10-K · filed 2026-02-05 |
| 2024-09-30 | $14.19M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $14.27M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $14.33M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $14.39M 10-K · filed 2025-03-03 |
| 2023-09-30 | $14.51M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $14.64M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $13.80M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $13.96M 10-K · filed 2024-03-11 |
| 2022-09-30 | $14.14M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $14.19M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $14.31M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $13.00M 10-K · filed 2023-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |